TODAY'S MARKET INTELLIGENCE
Taienkang: Subsidiary Receives Clinical Trial Approval Notice for Cisplatin Polymer Micelle Injection
English summary
Taienkang's wholly-owned subsidiary Shandong Huabo Kaisheng Biotech received a clinical trial approval notice from the NMPA for its cisplatin polymer micelle injection (Category 2.2 chemical drug) for monotherapy in advanced malignant tumors. The drug aims to reduce toxicity and achieve passive targeting; no domestic company has obtained a registration approval yet.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence